Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Cancer Research|2022Cited by 160
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysisValerie Calvert, Zobair M. Younossi|Hepatology|2007Cited by 51
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Kristina Drizyte‐Miller et al.|UNC Libraries|2024Cited by 12
Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Unknown|2023Cited by 0
Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Unknown|2023Cited by 0